David’s News.

Less noise.
More perspective.

Your catch-upNo must-know briefs right now
Wednesday, October 7Live · checked 12 min ago
Back to your briefing
Science · AI-written · Source-verified

UK regulator approves catumaxomab for cancer-related abdominal fluid build-up

The MHRA says the medicine is for adults with malignant ascites when standard cancer treatment is no longer feasible.

David’s News · AI-written; checked against cited sources. Checks can still miss errors.
https://davids.news/s/uk-regulator-approves-catumaxomab-for-cancer-related-abdominal-fluid-build-up-034b217d
Read as Markdown Reading style
·Single primary source·First edition
  • The MHRA says catumaxomab, marketed as Korjuny, may extend the time between fluid-drainage procedures.
  • The regulator says it will continue reviewing the medicine’s safety and effectiveness.
Why it matters

The approval adds a treatment option for adults with malignant ascites, according to the MHRA.

What’s next

The MHRA says it will keep catumaxomab under safety and effectiveness review.

Read the originals

A little more context

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced approval of catumaxomab, marketed as Korjuny, for adults with malignant ascites when standard cancer treatment is no longer feasible. The agency describes malignant ascites as cancer-cell-containing fluid accumulating in the abdomen, which patients may need procedures to drain.

The MHRA says catumaxomab is a monoclonal antibody that targets EpCAM, a protein on certain cancer cells, and activates immune cells to help destroy them. It says the treatment can extend the time between drainage procedures. The agency said it will continue monitoring the medicine’s safety and effectiveness.

Go straight to the source

UK Government
Primary source · www.gov.uk

Every factual claim links back to the reporting. We summarize in our own words.

The story’s history

  1. Version 1 · 4 hr ago

    First verified brief published.

How this brief is grounded

UK regulator approves catumaxomab for cancer-related abdominal fluid build-upUK Government

The MHRA says the medicine is for adults with malignant ascites when standard cancer treatment is no longer feasible.UK Government

The MHRA says catumaxomab, marketed as Korjuny, may extend the time between fluid-drainage procedures.UK Government

The regulator says it will continue reviewing the medicine’s safety and effectiveness.UK Government

The approval adds a treatment option for adults with malignant ascites, according to the MHRA.UK Government

The MHRA says it will keep catumaxomab under safety and effectiveness review.UK Government

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced approval of catumaxomab, marketed as Korjuny, for adults with malignant ascites when standard cancer treatment is no longer feasible.UK Government

The agency describes malignant ascites as cancer-cell-containing fluid accumulating in the abdomen, which patients may need procedures to drain.UK Government

The MHRA says catumaxomab is a monoclonal antibody that targets EpCAM, a protein on certain cancer cells, and activates immune cells to help destroy them.UK Government

It says the treatment can extend the time between drainage procedures.UK Government

The agency said it will continue monitoring the medicine’s safety and effectiveness.UK Government

Open topic

Other recent briefs sharing a topic or named subject. Each is a separate report.

Science/YesterdayRead30 sec

UK government accepts 44 recommendations on healthcare AI regulation

The government says it will deliver the commission’s recommendations across the UK; the MHRA has opened applications for a third AI Airlock phase.

UK GovernmentRead briefClose brief
  • The government said it accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare.
  • The MHRA opened applications for the third phase of its regulatory sandbox for AI-enabled medical devices.
Why it matters

The response sets out a government plan for regulating AI in healthcare.

What’s next

The MHRA is taking applications for the sandbox’s third phase.

Single primary sourceUK Government
Go deeper
Listen to this brief~30 sec
AI voice · Same verified brief
AI-written · Source-verifiedv1
Business/6 hr agoRead30 sec

UK authority proposes anti-dumping duty on Chinese titanium dioxide

The Trade Remedies Authority says its initial recommendation follows findings of dumping and an imminent threat of injury to UK producers.

UK GovernmentRead briefClose brief
  • The proposal concerns rutile titanium dioxide imports from China, used in products including coatings, plastics and paper.
  • The Trade Remedies Authority published the initial recommendation; the source does not specify the proposed duty rate.
Why it matters

The recommendation could lead to a new trade measure affecting imports of an industrial whitening agent.

What’s next

The source reports an initial recommendation, not a final measure.

Single primary sourceUK Government
Go deeper
AI-written · Source-verifiedv1
Politics/YesterdayRead30 sec

UK department adds contact strategy trial report to survey methodology page

The Department for Digital, Culture, Media and Sport says its Community and Engagement Survey 2025/26 report is now included.

Original report: Sep 30, 2026

UK Culture DepartmentRead briefClose brief
  • The page gathers methodology documents for the survey, according to the department.
Why it matters

The update makes the trial report available alongside the survey’s methodology materials.

Single primary sourceUK Culture Department
Go deeper
AI-written · Source-verifiedv1

Find a little clarity.

Search verified briefs, publisher headlines, and community events.